|Bid||0.570 x 0|
|Ask||0.596 x 0|
|Day's Range||0.540 - 0.580|
|52 Week Range||0.078 - 0.589|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
TORONTO , Sept.18, 2018 /CNW/ - FSD Pharma Inc. (HUGE.CN) (FSDDF) (0K9.F) ("FSD Pharma" or the "Company), which, through its wholly-owned subsidiary FV Pharma Inc., is a licensed producer pursuant to the Access to Cannabis for Medical Purposes Regulations, is pleased to announce that it has signed a definitive collaboration and profit sharing agreement (the "Agreement") with Canntab Therapeutics Limited (CSE:PILL) ("Canntab"), a leader in the rapidly growing cannabis pill market, effective September 17, 2018 . Under the terms of the Agreement, FSD Pharma will assist Canntab to obtain a license to process and sell cannabis products pursuant to the Cannabis Act (the "License"), and will provide Canntab with space at its facility (the "FSD Facility"), which is located just one hour east of Toronto in Cobourg, Ontario (the "Transaction").
TORONTO , Sept. 12, 2018 /CNW/ - FSD Pharma Inc. ("FSD" or the "Company") (HUGE.CN) (FSDDF) (0K9.F), is pleased to report that on September 11, 2018 the Company traded an aggregate total of exactly 213,761,823 shares. FSD traded 143,260,988 Class B subordinate voting shares on the Canadian Securities Exchange ("CSE"), 1,888,500 on AQC-Lit, 15,369,000 on AQC-Neo, 241,740 on CXC, 5,309,399 on CX2, 6,473,592 on CXD, 22,500 on Lynx, 24,750,500 on Omega and 16,445,604 on MatchNow. This is the largest total quantity of share volume traded by a CSE listed issuer by over 15.7% above the recorded all-time high of 184,718,114 also achieved by FSD on September 10, 2018 , as confirmed by the CSE.
TORONTO , Sept. 11, 2018 /CNW/ - FSD Pharma Inc. ("FSD Pharma" or the "Company") (HUGE.CN) (FSDDF) (0K9.F) announces that pursuant to its Stock Option Plan, the Board approved the grant of 3,000,000 stock options for class B subordinate voting shares of the Company (the "Options") on August 14, 2018 to Dr. Raza Bokhari following his appointment as a Director. The Board has also approved an additional grant of 40,000,000 Options to Dr. Bokhari exercisable at a price of $0.74 for a period of five years.
FSD Pharma Congratulates High Tide Ventures for Selection as Supplier to Ontario Cannabis Retail Corporation
TORONTO , Aug. 30, 2018 /CNW/ - FSD Pharma Inc. ("FSD Pharma" or the "Company") (HUGE.CN) (FSDDF) reported its financial and operational results for the second quarter of fiscal 2018, ended June 30 th, 2018. These filings are available for review on the Company's SEDAR profile at www.sedar.com. FSD Pharma continues to make Strategic early stage investments in the Cannabis industry with like minded companies that 1) provide excellent investment potential and 2) will assist FSD strategically in its business. An example of this is evidenced by this quarters mark to market asset revaluation of FSD's holding in Cannara Biotech resulting in a $7,500,000 gain.
TORONTO , Aug. 23, 2018 /CNW/ - FSD Pharma Inc. ("FSD Pharma" or "FSD") (HUGE.CN) (FSDDF) (0K9.F) reports today that its strategic R&D partner, SciCann Therapeutics Inc. ("SciCann"), has achieved positive results in a pre-clinical efficacy study of its proprietary "Steady Stomach" CBD combination product for Inflammatory Bowel Disease (IBD).
This comprehensive clinical research program will be executed through SciCann's strategic alliance and collaboration agreement with Mor Research Applications Ltd. ("Mor") - the technology transfer office and commercial arm of Clalit Healthcare Services, Israel's largest medical insurer and healthcare provider, which operates a network of 14 full scale hospitals throughout Israel , employs over 9,000 physicians and serves the healthcare needs of over 50% of Israel's population.